Rationally Evolving MCP-1/CCL2 into a Decoy Protein with Potent Anti-inflammatory Activity in Vivo

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2010 Jan 26

PMID 20097750

Citations 22

Authors

Anna Maria Piccinini

Kerstin Knebl

Angelika Rek

Gerhild Wildner

Maria Diedrichs-Mohring

Andreas J Kungl

Affiliations

Soon will be listed here.

Abstract

Leukocyte recruitment from the blood into injured tissues during inflammatory diseases is the result of sequential events involving chemokines binding to their GPC receptors as well as to their glycosaminoglycan (GAG) co-receptors. The induction and the crucial role of MCP-1/CCL2 in the course of diseases that feature monocyte-rich infiltrates have been validated in many animal models, and several MCP-1/CCL2 as well as CCR2 antagonists have since been generated. However, despite some of them being shown to be efficacious in a number of animal models, many failed in clinical trials, and therapeutically interfering with the activity of this chemokine is not yet possible. We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked out CCR2 activity, which were designed to interrupt the MCP-1/CCL2-related signaling cascade. We provide evidence that our lead mutant MCP-1(Y13A/S21K/Q23R) exhibits a 4-fold higher affinity toward the natural MCP-1 GAG ligand heparan sulfate and that it shows a complete deficiency in activating CCR2 on THP-1 cells. Furthermore, a significantly longer residual time on GAG ligands was observed by surface plasmon resonance. Finally, we were able to show that MCP-1(Y13A/S21K/Q23R) had a mild ameliorating effect on experimental autoimmune uveitis and that a marginal effect on oral tolerance in the group co-fed with Met-MCP-1(Y13A/S21K/Q23R) plus immunogenic peptide PDSAg was observed. These results suggest that disrupting wild type chemokine-GAG interactions by a chemokine-based antagonist can result in anti-inflammatory activity that could have potential therapeutic implications.

Citing Articles

Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.

Gschwandtner M, Gammage A, Deligne C, Mies L, Domaingo A, Murdamoothoo D Int J Mol Sci. 2023; 24(9).

PMID: 37176074 PMC: 10179296. DOI: 10.3390/ijms24098365.

Isolation and Characterization of Heparan Sulfate from Human Lung Tissues.

Derler R, Kitic N, Gerlza T, Kungl A Molecules. 2021; 26(18).

PMID: 34576979 PMC: 8469465. DOI: 10.3390/molecules26185512.

Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response.

Chaari A, Bendriss G, Zakaria D, McVeigh C Front Public Health. 2020; 8:476.

PMID: 32984253 PMC: 7481450. DOI: 10.3389/fpubh.2020.00476.

Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation.

Crijns H, Vanheule V, Proost P Front Immunol. 2020; 11:483.

PMID: 32296423 PMC: 7138053. DOI: 10.3389/fimmu.2020.00483.

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis.

Gschwandtner M, Derler R, Midwood K Front Immunol. 2020; 10:2759.

PMID: 31921102 PMC: 6923224. DOI: 10.3389/fimmu.2019.02759.

References

Grewal I, RUTLEDGE B, Fiorillo J, Gu L, Gladue R, Flavell R . Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J Immunol. 1997; 159(1):401-8. View

Gong J, Ratkay L, Waterfield J, Clark-Lewis I . An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med. 1997; 186(1):131-7. PMC: 2198969. DOI: 10.1084/jem.186.1.131. View

Boring L, Gosling J, Cleary M, Charo I . Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394(6696):894-7. DOI: 10.1038/29788. View

Bruhl H, Cihak J, Schneider M, Plachy J, Rupp T, Wenzel I . Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol. 2004; 172(2):890-8. DOI: 10.4049/jimmunol.172.2.890. View

Macdermott R . Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999; 19(5):266-72. DOI: 10.1023/a:1020583306627. View

Nakano K, Egashira K, Ohtani K, Zhao G, Funakoshi K, Ihara Y . Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis. 2006; 194(2):309-16. DOI: 10.1016/j.atherosclerosis.2006.10.029. View

Dawson T, Kuziel W, Osahar T, Maeda N . Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999; 143(1):205-11. DOI: 10.1016/s0021-9150(98)00318-9. View

Gong J, Yan R, Waterfield J, Clark-Lewis I . Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology (Oxford). 2003; 43(1):39-42. DOI: 10.1093/rheumatology/keg459. View

Koch A, Kunkel S, Harlow L, Johnson B, Evanoff H, Haines G . Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992; 90(3):772-9. PMC: 329929. DOI: 10.1172/JCI115950. View

10.

Schepers A, Eefting D, Bonta P, Grimbergen J, de Vries M, van Weel V . Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2006; 26(9):2063-9. DOI: 10.1161/01.ATV.0000235694.69719.e2. View

11.

Potzinger H, Geretti E, Brandner B, Wabitsch V, Piccinini A, Rek A . Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem Soc Trans. 2006; 34(Pt 3):435-7. DOI: 10.1042/BST0340435. View

12.

Brodmerkel C, Huber R, Covington M, Diamond S, Hall L, Collins R . Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol. 2005; 175(8):5370-8. DOI: 10.4049/jimmunol.175.8.5370. View

13.

Boring L, Gosling J, Monteclaro F, Lusis A, Tsou C, Charo I . Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein 1alpha receptors: evidence for two closely linked C-C chemokine receptors on chromosome 9. J Biol Chem. 1996; 271(13):7551-8. DOI: 10.1074/jbc.271.13.7551. View

14.

Kuziel W, Morgan S, Dawson T, Griffin S, SMITHIES O, Ley K . Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A. 1997; 94(22):12053-8. PMC: 23699. DOI: 10.1073/pnas.94.22.12053. View

15.

Mo J, Matsukawa A, Ohkawara S, Yoshinaga M . Role and regulation of IL-8 and MCP-1 in LPS-induced uveitis in rabbits. Exp Eye Res. 1999; 68(3):333-40. DOI: 10.1006/exer.1998.0618. View

16.

Handel T, Johnson Z, Rodrigues D, Dos Santos A, Cirillo R, Muzio V . An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol. 2008; 84(4):1101-8. PMC: 2538597. DOI: 10.1189/jlb.0108061. View

17.

Handel T, Johnson Z, Crown S, Lau E, Proudfoot A . Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem. 2005; 74:385-410. DOI: 10.1146/annurev.biochem.72.121801.161747. View

18.

de Smet M, Bitar G, Roberge F, Gery I, Nussenblatt R . Human S-antigen: presence of multiple immunogenic and immunopathogenic sites in the Lewis rat. J Autoimmun. 1993; 6(5):587-99. DOI: 10.1006/jaut.1993.1048. View

19.

Hohensinner P, Kaun C, Rychli K, Cohen E, Kastl S, Demyanets S . Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett. 2006; 580(14):3532-8. DOI: 10.1016/j.febslet.2006.05.043. View

20.

Nelken N, Coughlin S, Gordon D, Wilcox J . Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88(4):1121-7. PMC: 295565. DOI: 10.1172/JCI115411. View